Durable Disease Control with Obexelimab in IgG4-Related Disease: Phase 3 INDIGO Open-Label Extension (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB18; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; No abstract available
Clinical • Late-breaking abstract • P3 data • Inflammation
|